AVIXA Report: Increasing Costs Slow Demand in April
The AV Sales Index (AVI-S) for April dropped 7.3 points to 52.2, with 21% of survey respondents reporting they saw a decrease in sales for the month. This most likely means buyers are still active but are moderating spend, leading to softer revenue outcomes despite continued deployment activity. Companies are stating they have a good pipeline through 2026.
Tariff uncertainty, geopolitical conflict, and economic instability are the dominant concerns, making it difficult to forecast, price projects, and close sales. However, seasonal patterns in education and a few other vertical markets provide optimism for the coming months.
“Constantly changing tariff add-ons make it difficult to provide clients with accurate cost assessment for projects. In addition, frustration with paying tariffs to vendors knowing they'll be the ones to collect any refunds instead of giving them back makes one question the legality of vendors even being allowed to charge them to us in the first place,” shared an end user in North America.
The March AV Employment Index (AVI-E) remained steady at 54.2 in April. The U.S. job growth rebounded but at a slower pace than last year’s norms. Some are finding it hard to hire skilled employees while others are freezing hiring.
The Pro AV Business Index report is derived from a monthly survey of the AVIXA Insights Community, a research community of industry members that tracks business trends in commercial AV. The report comprises two diffusion indexes: the AV Sales Index (AVI-S) and the AV Employment Index (AVI-E). In each case, an index above 50 indicates an increase in sales or employment activity.
Visit www.avixa.org/AVindex to access the free monthly Pro-AV Business Index reports and learn more about the methodology. For more information about joining the AVIXA Insights Community, visit www.avixa.org/AVIP.
A daily selection of the top stories for AV integrators, resellers and consultants. Sign up below.
Erin Budnik is the manager of market insight for AVIXA.
